Caris Life Sciences Inc 2025年季度报告

(Mark One)☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period endedJune30, 2025 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transion period from ____ to ____ CARIS LIFE SCIENCES, INC. (Exact name of registrant as specified in its charter)_________________________________________ 85-2077369 (I.R.S. Employer Idenficaon Number) 750 W. John Carpenter FreewaySuite 800Irving,TX75039(Address of principal execuve offices, including ZIP code) Registrant’s telephone number, including area code: (866)771-8946 Securies registered pursuant to Secon 12(b) of the Act: The Nasdaq Stock Market LLC Indicate by check mark whether the registrant (1) hasfiled all reports required to befiled by Secon 13 or 15(d) of the Securies Exchange Actof 1934 during the preceding 12 months (or for such shorter period that the registrant was required tofile such reports), and (2) has beensubject to suchfiling requirements for the past 90 days. Yes☐No☒ Indicate by check mark whether the registrant has submied electronically every Interacve Data File required to be submied pursuant toRule 405 of Regulaon S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant wasrequired to submit suchfiles).Yes☒No☐ Indicate by check mark whether the registrant is a large acceleratedfiler, an acceleratedfiler, a non-acceleratedfiler, a smaller reporngcompany, or an emerging growth company. See the definions of “large acceleratedfiler,” “acceleratedfiler,” “smaller reporng company,”and “emerging growth company” in Rule 12b-2 of the Exchange Act. If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transion period for complyingwith any new or revisedfinancial accounng standards provided pursuant to Secon 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes☐No☒ As of August7, 2025, the registrant had281,224,124shares of common stock, par value $0.001 par per share, outstanding. CARIS LIFE SCIENCES, INC.FORM 10-Q TABLE OF CONTENTS Special Note Regarding Forward-Looking Statements This Quarterly Report on Form 10-Q (this “Quarterly Report”) contains forward-looking statements within the meaning of the PrivateSecuries Ligaon Reform Act of 1995 and other federal securies laws. All statements other than statements of historical facts contained inthis Quarterly Report, including statements regarding our expectaons of future results of operaons andfinancial condion, businessstrategy, soluons, technology, R&D costs, regulatory approvals, potenal market opportunity, ancipated trends in our business,ming andlikelihood of success, as well as plans and objecves of management for future operaons, are forward-looking statements. These statementsinvolve known and unknown risks, uncertaines, and other important factors that are in some cases beyond our control and may cause ouractual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed orimplied by the forward-looking statements. The words “ancipate,” “believe,” “contemplate,” “connue,” “could,” “esmate,” “expect,” “intend,” “may,” “plan,” “potenal,”“predict,” “project,” “should,” “target,” “will,” or “would,” or the negave of these terms or other similar expressions, are intended to idenfyforward looking statements. Forward-looking statements contained in this Quarterly Report include, but are not limited to, statements about: •developments in the precision oncology industry, including our biopharma partners’ use of molecular informaon and the marketsize for molecular informaon services;•our expectaons as to our addressable U.S. market in oncology, futurefinancial performance, results of operaons, or otheroperaonal results or metrics;•the ability of the Caris plaorm to help our biopharma partners and physicians improve the efficiency and success of theirtherapeuc development, and clinical programs;•our ability to scale the Caris plaorm and develop new soluons or enhancements to exisng soluons;•our ability to capture, aggregate, analyze, or otherwise ulize molecular informaon in novel ways;•our ability to compete with companies that are currently in, or may in the future enter, the industry in which we operate;•third-party payer reimbursement and coverage decisions;•our ability to establish, maintain, protect, and enforce our intellectual property rights of our soluons;•federal, state, and foreign regulatory requirements, including FDA regulaon of our soluons;•theming, likelihood, or condions of regulatoryfilings and approvals;•our ability to hire and retain key personnel;•our ancipated cash needs and our esmates regarding our capital requirements;•our esmates